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93* Hypertonic saline: effect on mucus rheology and spirometry
N. De Cono1, P. Schelstraete1, F. Haerynck1, S. Van daele1, N. Sanders2,
F. De Baets1. 1CF centre, University Hospital, Ghent, Belgium; 2FWO institute,
University Ghent, Ghent, Belgium
We studied the effect of NaCl 7% (HS) on sputum rheology and lung function in
stable CF patients.
Measurements (T0) of mucus rheology (Elasticity G′, Viscosity G′′), FEV1 and
FVC were done in 36 patients. Patients with a decrease in FEV1 of 8% after HS
were enrolled in the control group. 10 control (20±10 y) and 21 study patients
(23±8 y) were included. FEV1 was 76±21% and 62±22%, FVC 95±11% and
82±17% (p = 0.04) in the control and the HS group respectively.
At T1 after one inhalation with HS, measurements were repeated. The HS group
was treated with 4ml HS twice daily, the control group with 4ml NaCl 0.9% (NS).
After 4 weeks (T2) measurements were repeated.
A single inhaled dose of HS reduced mucus visco-elasticity in 78% of the patients.
Mean decrease of elasticity and viscosity was 52±23% and 44±22% respectively
(p< 0.001). FVC and FEV1 decreased with respectively 7% (CI 4.1 to 10.5,
p< 0.001) and 6.5% (CI 3.9 tot 8.4, p< 0.001).
At T2 a decrease in G′ and G′′ was measured in 63% of the patients in the HS
group and 75% of the NS group: G′ and G′′ in the HS group were 50±23% and
48±22% respectively, in the NS group 23.5±15% and 18±15% respectively. On
T2 no signiﬁcant decrease of mucus viscosity and elasticity was observed in the
HS group. FVC decreased in 75% of the HS group (3.5%, CI 0.8 to 6.2, p = 0.015)
and in 71% of the NS patients (2.7%, CI −2.6 to 8.1, p = 0.24). FEV1 decreased
in 70% of the HS patients (4.2%, CI 0.6 to 7.7, p = 0.026) and in 63% of the NS
patients (NS).
A single inhaled dose of HS decreased mucus viscosity and elasticity signiﬁcantly
but had adverse effects on spirometry. After 4 weeks therapy with HS we noticed
a trend towards decreased sputum viscosity and elasticity, however a signiﬁcant
decrease in FVC and FEV1 was observed.
94* b-adrenergic stimulation alters sweat gland potential difference in
cystic ﬁbrosis (CF) patients but not healthy controls
T. Gonska1, W. Ip1, C. Bear1, P. Durie1, P. Quinton2. 1Hospital for Sick Children,
University of Toronto, Toronto, ON, Canada; 2UC Riverside and UC School of
Medicine, La Jolla, CA, USA
Background: New therapies aiming to overcome the basic CFTR defect are
hampered by the lack of a practical, sensitive and reliable in vivo test of CFTR
function. We recently described a novel method of measuring the transglandular
potential difference (ESPD) in sweat glands following cholinergic stimulation which
shows promise as outcome measure in clinical trials.
Method: In this study we compared the effects of cholinergic (pilocarpine 1%)
and cholinergic plus b-adrenergic (aminophylline 0.8% and isoproterenol 1%)
stimulation on sweat gland function, by measuring: 1) ESPD using an ECG
electrode, 2) potential difference in single sweat droplets (SPD), 3) sweat rate and
4) sweat chloride concentration.
Results: Addition of b-adrenergic agonists had no effect on sweat rate or sweat
chloride concentration. However, cholinergic plus b-adrenergic stimulation resulted
in signiﬁcant reduction in ESPD and SPD in pancreatic sufﬁcient (CFPS) and
insufﬁcient (CFPS) patients, but not in healthy controls or obligate heterozygotes.
The Table shows mean difference between paired experiments,±standard error
(number of subjects), and student t-test with p< 0.001(*).
Conclusion: The exact mechanism for these observations remains to be elucidated.
However, ESPD measurements with cholinergic and b-adrenergic agents may be a
useful in vivo test of CFTR function.
Supported by: CCFF (Breathe Project).
Healthy Hetero CFPS CFPI
DSweat rate (ml/min) 0.43±0.24 (10) −0.25±0.17 (8) 0.34±0.19 (10) 0.13±0.37 (7)
DSweat chloride (mmol/L) 0.2±2.1 (10) 1.1±1.8 (8) 0.9±4.2 (8) −1.6±2.1 (8)
DSPD (mV) −7.9±4.4 (7) −5.5±5.6 (5) −14.8±3.8 (8)* −6.8±6.9 (6)
DESPD (mV) −1.3±2.2 (8) −0.14±1.8 (8) −18.3±2.6 (10)* −20.7±3.7 (8)*
*p< 0.001.
95 The effect of N-acetylcysteine on chloride efﬂux from
airway epithelial cells
G. Varelogianni1, I. Oliynyk1,2, G.M. Roomans1, M. Johannesson2. 1Medical Cell
Biology, Uppsala University, Uppsala, Sweden; 2CF Center, Uppsala University
Hospital, Uppsala, Sweden
Defective chloride (Cl−) transport in epithelial cells decreases mucus viscosity
and leads to recurrent infections and oxidative stress among Cystic Fibrosis (CF)
patients. We investigated whether N-acetylcysteine (NAC), a well known mucolytic
and antioxidant drug, could also stimulate Cl− efﬂux from CF and non-CF epithelial
cells.
CF bronchial epithelial cells (CFBE) were treated with 1mM, 5mM, 10mM or
15mM NAC and normal bronchial epithelial cells (16HBE) with 10mM NAC, for
2 h at 37ºC.
MQAE ﬂuorescence assay: Cells were loaded with the ﬂuorescent probe MQAE
for 2 h prior to analysis. Cover slips were placed as bottom in a perfusion chamber
on the stage of an inverted microscope. The effect of NAC on Cl− transport was
measured by exposure to a Cl− free buffer.
X-ray microanalysis (XRMA) of the intracellular elemental content: The CFBE and
16HBE cells were seeded on titanium mesh grids, treated with NAC as described
above, frozen and freeze dried. XRMA of the intracellular elemental content was
performed in a Hitachi H7100 electron microscope at 100 kV accelerating voltage.
Cl− efﬂux from CFBE cells was stimulated by NAC in a dose-dependent manner.
10mM NAC caused a signiﬁcant increase in Cl− efﬂux with nearly 80%. This
corresponded to about 40% of the efﬂux in 16HBE cells. Moreover, the intracellular
Cl− concentration in CFBE cells was signiﬁcantly decreased up to 60% after 2 h
treatment with 10mM of NAC. NAC did not affect Cl− efﬂux from 16HBE cells.
The stimulation of Cl− efﬂux in CF airway epithelial cells induced by NAC could
improve hydration of the mucus and might be beneﬁcial for the treatment of CF
patients.
96 Preliminary results of oxidative status change in cystic ﬁbrosis (CF)
and oral addition with cysteine
A. De Alessandri1, S. Beschi1, R. Casciaro1, C. Zucchi1, T. Mora1, L. Minicucci1.
1Cystic Fibrosis Centre, Istituto G Gaslini, Genua, Italy
Oxidative status has a role in the progressive lung damage in CF. Glutathione is
a defence from pro-antioxidant agents and it is reduced in CF. Cysteine is the
amino-acid that gives to glutathione the antioxidant status.
The objective of this study is to reduce the oxidative status in CF with a daily oral
addition of whey protein isolate with high content of cysteine.
Oxidative status is estimated on a blood sample with d-ROMs test and BAP test
that can measure oxidative stress and antioxidant status respectively. Patients will
be checked every three months. We recruited 32 patients still now.
All cases show a pathological condition of oxidative status. Oxidative stress is
increased in all patients and in the 52% of cases is very serious. Antioxidant status
is normal in the 46% of cases and the 14% show a high deﬁciency. Five patients
deserted the study for a bad compliance to the administration of cysteine.
In 9 compliant patients we have done the ﬁrst control after three months from the
recruitment. No adverse effect has been reported. All these cases show an improved
oxidative status. Oxidative stress has become normal in one patient. Antioxidant
status has become normal in 5 cases. Respiratory and nutritional conditions are
stable in 5 cases and improved in 4. Collected data conﬁrm a high level of oxidative
status in CF. Oral addition of cysteine seems efﬁcacious to improve the oxidative
status. Oxidative status improvement could correlate to a clinical improvement.
These observations coming from preliminary data must be conﬁrmed. We think
useful to continue the valuation of the efﬁcacy of oral addition of cysteine and we
consider antioxidant therapy potentially important in CF.
